JP Morgan played a pivotal role as the sole placement agent in Beacon Therapeutics’ recent achievement of securing $170 million during its Series B funding round.
Led by Forbion, a renowned life sciences venture capital firm, the investment will expedite the development of Beacon’s innovative ophthalmic gene therapies.
These include their leading asset,
You must be logged in to post a comment.